{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:03:39Z","timestamp":1786982619767,"version":"build-2736575974"},"reference-count":205,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,7]],"date-time":"2023-08-07T00:00:00Z","timestamp":1691366400000},"content-version":"vor","delay-in-days":310,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1007\/s13311-022-01277-w","type":"journal-article","created":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T15:02:31Z","timestamp":1662130951000},"page":"1752-1771","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Nervous system (NS) Tumors in Cancer Predisposition Syndromes"],"prefix":"10.1016","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2855-1555","authenticated-orcid":false,"given":"Prabhumallikarjun","family":"Patil","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bojana Borislavova","family":"Pencheva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinayak Mahesh","family":"Patil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Fangusaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1007\/s13311-022-01277-w_bib1","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1038\/s41591-020-1072-4","article-title":"Whole genome, transcriptome and methylome profiling enhances actionable target discovery in high-risk pediatric cancer","volume":"26","author":"Wong","year":"2020","journal-title":"Nat Med"},{"key":"10.1007\/s13311-022-01277-w_bib2","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1056\/NEJMoa1508054","article-title":"Germline mutations in predisposition genes in pediatric cancer","volume":"373","author":"Zhang","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1007\/s13311-022-01277-w_bib3","first-page":"159","article-title":"Lessons from hereditary colorectal cancer","volume":"87","author":"Kinzler","year":"1996","journal-title":"Cell press"},{"key":"10.1007\/s13311-022-01277-w_bib4","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nrc2399","article-title":"Cellular mechanisms of tumour suppression by the retinoblastoma gene","volume":"8","author":"Burkhart","year":"2008","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"10.1007\/s13311-022-01277-w_bib5","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S0031-3955(16)38298-0","article-title":"Nontraditional inheritance","volume":"39","author":"Austin","year":"1992","journal-title":"Pediatr Clin North Am"},{"key":"10.1007\/s13311-022-01277-w_bib6","series-title":"Genetics, Mosaicism","author":"Milani","year":"2021"},{"key":"10.1007\/s13311-022-01277-w_bib7","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1158\/1078-0432.CCR-17-0834","article-title":"Genetic counselor recommendations for cancer predisposition evaluation and surveillance in the pediatric oncology patient","volume":"23","author":"Druker","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1007\/s13311-022-01277-w_bib8","unstructured":"NCI Dictionary of Genetic Terms [online]. Available from: https:\/\/www.cancer.gov\/publications\/dictionaries\/genetics-dictionary\/def\/cascade-screening. Accessed 3 Aug 2022."},{"key":"10.1007\/s13311-022-01277-w_bib9","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1200\/JCO.2016.66.6552","article-title":"immune checkpoint inhibition for hypermutant glioblastoma multiforme resulting from germline biallelic mismatch repair deficiency","volume":"34","author":"Bouffet","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1007\/s13311-022-01277-w_bib10","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s10897-005-9014-3","article-title":"A new definition of Genetic Counseling: National Society of Genetic Counselors' Task Force report","volume":"15","author":"Resta","year":"2006","journal-title":"J Genet Couns"},{"key":"10.1007\/s13311-022-01277-w_bib11","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1080\/14728222.2018.1465931","article-title":"Emerging therapeutic targets for neurofibromatosis type 1","volume":"22","author":"Walker","year":"2018","journal-title":"Expert Opin Ther Targets"},{"key":"10.1007\/s13311-022-01277-w_bib12","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/S1474-4422(14)70063-8","article-title":"Neurofibromatosis type 1: a multidisciplinary approach to care","volume":"13","author":"Hirbe","year":"2014","journal-title":"Lancet Neurol"},{"key":"10.1007\/s13311-022-01277-w_bib13","doi-asserted-by":"crossref","first-page":"14087","DOI":"10.1523\/JNEUROSCI.3242-12.2012","article-title":"Neurofibromatosis type 1: modeling CNS dysfunction","volume":"32","author":"Gutmann","year":"2012","journal-title":"J Neurosci"},{"key":"10.1007\/s13311-022-01277-w_bib14","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1212\/01.WNL.0000144341.16830.01","article-title":"Late-onset optic pathway tumors in children with neurofibromatosis 1","volume":"63","author":"Listernick","year":"2004","journal-title":"Neurology"},{"key":"10.1007\/s13311-022-01277-w_bib15","first-page":"773","volume":"22","author":"Packer","year":"2009","journal-title":"Implications of new understandings of gliomas in children and adults with NF1:report of a consensus conference"},{"key":"10.1007\/s13311-022-01277-w_bib16","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1002\/ajmg.a.20211","article-title":"Optic pathway gliomas in neurofibromatosis type 1: the effect of presenting symptoms on outcome","volume":"122","author":"King","year":"2003","journal-title":"Am J Med Genet A"},{"key":"10.1007\/s13311-022-01277-w_bib17","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/WNO.0000000000000550","article-title":"Optic pathway gliomas in neurofibromatosis type 1: an update: surveillance, treatment indications, and biomarkers of vision","volume":"37","author":"De","year":"2017","journal-title":"J Neuroophthalmol"},{"key":"10.1007\/s13311-022-01277-w_bib18","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1002\/ajmg.a.20654","article-title":"Knowledge without truth: screening for complications of neurofibromatosis type 1 in childhood","volume":"127","author":"Listernick","year":"2004","journal-title":"Am J Med Genet A"},{"issue":"8","key":"10.1007\/s13311-022-01277-w_bib19","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1038\/s41436-021-01170-5","article-title":"Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation.","volume":"23","author":"Legius","year":"2021","journal-title":"Genet Med."},{"key":"10.1007\/s13311-022-01277-w_bib20","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/ana.21107","article-title":"Optic pathway gliomas in neurofibromatosis-1: Controversies and recommendations","volume":"61","author":"Listernick","year":"2007","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-022-01277-w_bib21","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1212\/01.wnl.0000257095.33125.48","article-title":"Moyamoya following cranial irradiation for primary brain tumors in children","volume":"68","author":"Ullrich","year":"2007","journal-title":"Neurology"},{"key":"10.1007\/s13311-022-01277-w_bib22","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1200\/JCO.1993.11.5.850","article-title":"Carboplatin and vincristine for recurrent and newly diagnosed low-grade gliomas of childhood","volume":"11","author":"Packer","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.1007\/s13311-022-01277-w_bib23","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1200\/JCO.2011.34.5843","article-title":"Phase II study of weekly vinblastine in recurrent or refractory pediatric low-grade glioma","volume":"30","author":"Bouffet","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1007\/s13311-022-01277-w_bib24","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1001\/jamaophthalmol.2013.5819","article-title":"Marked recovery of vision in children with optic pathway gliomas treated with bevacizumab","volume":"132","author":"Avery","year":"2014","journal-title":"JAMA Ophthalmol"},{"key":"10.1007\/s13311-022-01277-w_bib25","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S1470-2045(19)30277-3","article-title":"Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: A multicentre, phase 2 trial.","volume":"20","author":"Fangusaro","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1007\/s13311-022-01277-w_bib26","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1136\/jmg.2008.061051","article-title":"Longitudinal study of neurofibromatosis 1 associated plexiform neurofibromas","volume":"46","author":"Tucker","year":"2008","journal-title":"J Med Genet"},{"key":"10.1007\/s13311-022-01277-w_bib27","first-page":"6032","volume":"13","author":"Sanchez","year":"2021","journal-title":"Targeted therapies for the neurofibromatoses cancers (Basel)"},{"key":"10.1007\/s13311-022-01277-w_bib28","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1093\/neuonc\/noy067","article-title":"Association of plexiform neurofibroma volume changes and development of clinical morbidities in neurofibromatosis 1","volume":"20","author":"Gross","year":"2018","journal-title":"Neuro Oncol"},{"key":"10.1007\/s13311-022-01277-w_bib29","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1215\/15228517-2008-011","article-title":"Assessment of benign tumor burden by whole-body MRI in patients with neurofibromatosis 1","volume":"10","author":"Mautner","year":"2008","journal-title":"Neuro Oncol"},{"key":"10.1007\/s13311-022-01277-w_bib30","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1212\/WNL.56.11.1433","article-title":"The clinical and diagnostic implications of mosaicism in the neurofibromatoses","volume":"56","author":"Ruggieri","year":"2001","journal-title":"Neurology"},{"key":"10.1007\/s13311-022-01277-w_bib31","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/(SICI)1096-8628(19990326)89:1<31::AID-AJMG7>3.0.CO;2-W","article-title":"Plexiform neurofibromas","volume":"89","author":"Korf","year":"1999","journal-title":"Am J Med Genet"},{"key":"10.1007\/s13311-022-01277-w_bib32","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.jpeds.2011.04.008","article-title":"Plexiform neurofibromas in children with neurofibromatosis type 1: Frequency and associated clinical deficits","volume":"159","author":"Nguyen","year":"2011","journal-title":"J Pediatr"},{"key":"10.1007\/s13311-022-01277-w_bib33","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1001\/archderm.1993.01680260047004","article-title":"A controlled multiphase trial of ketotifen to minimize neurofibroma-associated pain and itching","volume":"129","author":"Riccardi","year":"1993","journal-title":"Arch Dermatol"},{"key":"10.1007\/s13311-022-01277-w_bib34","first-page":"1011","article-title":"Mast-cell stabilization to decrease neurofibroma growth","volume":"123","author":"Riccardi","year":"1987","journal-title":"Preliminary experience with ketotifen Arch Dermatol"},{"key":"10.1007\/s13311-022-01277-w_bib35","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1002\/pbc.25041","article-title":"Phase II trial of pirfenidone in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas","volume":"61","author":"Widemann","year":"2014","journal-title":"Pediatr Blood Cancer"},{"key":"10.1007\/s13311-022-01277-w_bib36","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0022-3565(24)38125-X","article-title":"Effects of pirfenidone on procollagen gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis","volume":"289","author":"Iyer","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1007\/s13311-022-01277-w_bib37","first-page":"311","article-title":"Pirfenidone inhibits PDGF isoforms in bleomycin hamster model of lung fibrosis at the translational level","volume":"276","author":"Gurujeyalakshmi","year":"1999","journal-title":"Am J Physiol"},{"key":"10.1007\/s13311-022-01277-w_bib38","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1212\/01.WNL.0000042321.94839.78","article-title":"Phase I study of thalidomide for the treatment of plexiform neurofibroma in neurofibromatosis 1","volume":"60","author":"Gupta","year":"2003","journal-title":"Neurology"},{"key":"10.1007\/s13311-022-01277-w_bib39","first-page":"289","article-title":"Phase II trial of pegylated interferon alfa-2b in young patients with neurofibromatosis type 1 and unresectable plexiform neurofibromas","volume":"19","author":"Jakacki","year":"2017","journal-title":"Neuro Oncol"},{"key":"10.1007\/s13311-022-01277-w_bib40","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1056\/NEJMoa1605943","article-title":"Activity of selumetinib in neurofibromatosis type 1-related plexiform neurofibromas","volume":"375","author":"Dombi","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1007\/s13311-022-01277-w_bib41","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1056\/NEJMoa1912735","article-title":"Selumetinib in children with inoperable plexiform neurofibromas","volume":"382","author":"Gross","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1007\/s13311-022-01277-w_bib42","first-page":"165","article-title":"Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial","volume":"27","author":"Fisher","year":"2021","journal-title":"Neurofibromatosis Clinical Trials Consortium"},{"key":"10.1007\/s13311-022-01277-w_bib43","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1002\/pbc.24873","article-title":"Sirolimus for non-progressive NF1-associated plexiform neurofibromas: an NF clinical trials consortium phase II study","volume":"61","author":"Weiss","year":"2014","journal-title":"Pediatr Blood Cancer"},{"key":"10.1007\/s13311-022-01277-w_bib44","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.jid.2018.09.016","article-title":"Absence of efficacy of everolimus in neurofibromatosis 1-related plexiform neurofibromas: results from a phase 2a trial","volume":"139","author":"Zehou","year":"2018","journal-title":"J Invest Dermatol"},{"key":"10.1007\/s13311-022-01277-w_bib45","first-page":"116","article-title":"Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial","volume":"381","author":"Franz","year":"2012","journal-title":"Lancet"},{"key":"10.1007\/s13311-022-01277-w_bib46","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/nrc3911","article-title":"A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor","volume":"15","author":"Ratner","year":"2015","journal-title":"Nat Rev Cancer"},{"key":"10.1007\/s13311-022-01277-w_bib47","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1136\/jmg.39.5.311","article-title":"Malignant peripheral nerve sheath tumours in neurofibromatosis 1","volume":"39","author":"Evans","year":"2002","journal-title":"J Med Genet"},{"key":"10.1007\/s13311-022-01277-w_bib48","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1517\/13543784.2013.772979","article-title":"Optimizing biologically targeted clinical trials for neurofibromatosis","volume":"22","author":"Gutmann","year":"2013","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1007\/s13311-022-01277-w_bib49","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.ijrobp.2008.03.073","article-title":"Clinical experience with radiation therapy in the management of neurofibromatosis-associated central nervous system tumors","volume":"73","author":"Wentworth","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1007\/s13311-022-01277-w_bib50","first-page":"50","article-title":"Genetics of human malignant peripheral nerve sheath tumors","volume":"2","author":"Pemov","year":"2019","journal-title":"Neurooncol Adv"},{"key":"10.1007\/s13311-022-01277-w_bib51","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1186\/1479-7364-5-6-623","article-title":"Neurofibromatosis type 1-associated tumours: their somatic mutational spectrum and pathogenesis.","volume":"5","author":"Spyk","year":"2011","journal-title":"Hum Genomics."},{"key":"10.1007\/s13311-022-01277-w_bib52","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1002\/ijc.32187","article-title":"Pediatric malignancies in neurofibromatosistype1: a population-based cohort study","volume":"145","author":"Peltonen","year":"2019","journal-title":"Int J Cancer"},{"key":"10.1007\/s13311-022-01277-w_bib53","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1158\/1078-0432.CCR-17-0589","article-title":"Cancer and central nervous system tumor surveillance in pediatric neurofibromatosis 1","volume":"23","author":"Evans","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1007\/s13311-022-01277-w_bib54","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1007\/s00330-020-07234-5","article-title":"Peripheral nerve sheath tumor: differentiation of malignant from benign tumors with conventional and diffusion-weighted MRI","volume":"31","author":"Yun","year":"2021","journal-title":"Eur Radiol"},{"key":"10.1007\/s13311-022-01277-w_bib55","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/s41591-018-0263-8","article-title":"The molecular landscape of glioma in patients with Neurofibromatosis 1","volume":"25","author":"D'Angelo","year":"2019","journal-title":"Nat Med"},{"key":"10.1007\/s13311-022-01277-w_bib56","doi-asserted-by":"crossref","first-page":"114","DOI":"10.3390\/cancers12010114","article-title":"An update on neurofibromatosis type 1-associated gliomas","volume":"12","author":"Lobbous","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1007\/s13311-022-01277-w_bib57","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1007\/s00415-014-7292-0","article-title":"Prolonged survival in adult neurofibromatosis type I patients with recurrent high-grade gliomas treated with bevacizumab","volume":"261","author":"Theeler","year":"2014","journal-title":"J Neurol"},{"key":"10.1007\/s13311-022-01277-w_bib58","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/00129492-200501000-00016","article-title":"Incidence of vestibular schwannoma and neurofibromatosis 2 in the North West of England over a 10-year period: Higher incidence than previously thought","volume":"26","author":"Evans","year":"2005","journal-title":"Otol Neurotol"},{"key":"10.1007\/s13311-022-01277-w_bib59","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1136\/jmg.40.2.109","article-title":"Molecular study of frequency of mosaicism in neurofibromatosis 2 patients with bilateral vestibular schwannomas","volume":"40","author":"Kluwe","year":"2003","journal-title":"J Med Genet"},{"key":"10.1007\/s13311-022-01277-w_bib60","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1097\/MAO.0000000000000272","article-title":"Neurofibromatosis type 2 vestibular schwannoma treatment: a review of the literature, trends, and outcomes","volume":"35","author":"Maniakas","year":"2014","journal-title":"Otol Neurotol"},{"key":"10.1007\/s13311-022-01277-w_bib61","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1093\/neuros\/nyx368","article-title":"Malignant peripheral nerve sheath tumors are not a feature of neurofibromatosis type 2 in the unirradiated patient","volume":"83","author":"King","year":"2018","journal-title":"Neurosurgery"},{"key":"10.1007\/s13311-022-01277-w_bib62","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1136\/jmedgenet-2017-104519","article-title":"Genetic severity score predicts clinical phenotype in NF2.","volume":"54","author":"Halliday","year":"2017","journal-title":"J Med Genet."},{"key":"10.1007\/s13311-022-01277-w_bib63","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1590\/S0004-282X2001000300009","article-title":"Behaviour of oligodendrocytes and Schwann cells in an experimental model of toxic demyelination of the central nervous system","volume":"59","author":"Gra\u00e7a","year":"2001","journal-title":"Arq Neuropsiquiatr"},{"key":"10.1007\/s13311-022-01277-w_bib64","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1097\/00129492-200109000-00024","article-title":"Elevation of internal auditory canal pressure by vestibular schwannomas.","volume":"22","author":"Badie","year":"2001","journal-title":"Otol Neurotol."},{"key":"10.1007\/s13311-022-01277-w_bib65","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/MAO.0b013e318248ee02","article-title":"Dysfunction of the cochlea contributing to hearing loss in acoustic neuromas: an underappreciated entity","volume":"33","author":"Roosli","year":"2012","journal-title":"Otol Neurotol"},{"key":"10.1007\/s13311-022-01277-w_bib66","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1097\/MAO.0b013e31825e73f5","article-title":"Bevacizumab for progressive vestibular schwannoma in neurofibromatosis type 2: a retrospective review of 31 patients","volume":"33","author":"Plotkin","year":"2012","journal-title":"Otol Neurotol"},{"key":"10.1007\/s13311-022-01277-w_bib67","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s11060-019-03234-8","article-title":"Efficacy and safety of bevacizumab for vestibular schwannoma in neurofibromatosis type 2: a systematic review and meta-analysis of treatment outcomes","volume":"144","author":"Lu","year":"2019","journal-title":"J Neurooncol"},{"key":"10.1007\/s13311-022-01277-w_bib68","doi-asserted-by":"crossref","first-page":"3446","DOI":"10.1200\/JCO.19.01367","article-title":"Prospective, phase II and biomarker study of high-dose bevacizumab as induction therapy in patients with neurofibromatosis type 2 and progressive vestibular schwannoma","volume":"37","author":"Plotkin","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1007\/s13311-022-01277-w_bib69","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1093\/neuonc\/nos146","article-title":"Phase II trial of lapatinib in adult and pediatric patients with neurofibromatosis type 2 and progressive vestibular schwannomas","volume":"14","author":"Karajannis","year":"2012","journal-title":"Neuro Oncol"},{"key":"10.1007\/s13311-022-01277-w_bib70","doi-asserted-by":"crossref","first-page":"951","DOI":"10.2214\/ajr.165.4.7676998","article-title":"Spinal tumors in patients with neurofibromatosis type 2: MR imaging study of frequency, multiplicity, and variety","volume":"165","author":"Mautner","year":"1995","journal-title":"AJR Am J Roentgenol"},{"key":"10.1007\/s13311-022-01277-w_bib71","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1093\/jnen\/60.10.994","article-title":"Aggressive phenotypic and genotypic features in pediatric and NF2-associated meningiomas: a clinicopathologic study of 53 cases","volume":"60","author":"Perry","year":"2001","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1007\/s13311-022-01277-w_bib72","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s00401-019-02029-5","article-title":"An update on the CNS manifestations of neurofibromatosis type 2","volume":"139","author":"Coy","year":"2019","journal-title":"Acta Neuropathol"},{"issue":"4","key":"10.1007\/s13311-022-01277-w_bib73","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1136\/jmg.2010.085241","article-title":"Cranial meningiomas in 411 neurofibromatosis type 2 (NF2) patients with proven gene mutations: clear positional effect of mutations, but absence of female severity effect on age at onset.","volume":"48","author":"Smith","year":"2011","journal-title":"J Med Genet."},{"key":"10.1007\/s13311-022-01277-w_bib74","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.3109\/00207454.2015.1092443","article-title":"Effect of bevacizumab on intracranial meningiomas in patients with neurofibromatosis type 2-A retrospective case series","volume":"126","author":"Alanin","year":"2016","journal-title":"Int J Neurosci"},{"key":"10.1007\/s13311-022-01277-w_bib75","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1007\/s11060-018-2922-5","article-title":"Effect of lapatinib on meningioma growth in adults with neurofibromatosis type 2","volume":"139","author":"Osorio","year":"2018","journal-title":"J Neurooncol"},{"key":"10.1007\/s13311-022-01277-w_bib76","doi-asserted-by":"crossref","first-page":"59941","DOI":"10.1371\/journal.pone.0059941","article-title":"Bevacizumab treatment for meningiomas in NF2: A retrospective analysis of 15 patients","volume":"8","author":"Nunes","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1007\/s13311-022-01277-w_bib77","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1158\/1078-0432.CCR-19-2109","article-title":"Everolimus and octreotide for patients with recurrent meningioma: results from the phase II CEVOREM.","author":"Graillon","year":"2020","journal-title":"Trial Clin Cancer Res."},{"key":"10.1007\/s13311-022-01277-w_bib78","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s11060-016-2172-3","article-title":"A phase II trial of bevacizumab and everolimus as treatment for patients with refractory, progressive intracranial meningioma","volume":"129","author":"Shih","year":"2016","journal-title":"J Neurooncol"},{"key":"10.1007\/s13311-022-01277-w_bib79","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jns.2018.07.018","article-title":"Meningioangiomatosis: a review of the variable manifestations and complex pathophysiology","volume":"15","author":"Tomkinson","year":"2018","journal-title":"J Neurol Sci"},{"key":"10.1007\/s13311-022-01277-w_bib80","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1750-3639.2005.tb00100.x","article-title":"Insights into meningioangiomatosis with and without meningioma: a clinicopathologic and genetic series of 24 cases with review of the literature","volume":"15","author":"Perry","year":"2005","journal-title":"Brain Pathol"},{"key":"10.1007\/s13311-022-01277-w_bib81","first-page":"709","article-title":"Meningioangiomatosis","volume":"122","author":"Wiebe","year":"1999","journal-title":"A comprehensive analysis of clinical and laboratory features Brain"},{"key":"10.1007\/s13311-022-01277-w_bib82","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1093\/jnen\/nly075","article-title":"A pediatric intra-axial malignant SMARCB1-deficient desmoplastic tumor arising in meningioangiomatosis.","volume":"77","author":"Rossi","year":"2018","journal-title":"J Neuropathol Exp Neurol."},{"key":"10.1007\/s13311-022-01277-w_bib83","doi-asserted-by":"crossref","first-page":"543","DOI":"10.3171\/2010.11.SPINE10350","article-title":"Spinal ependymomas in neurofibromatosis Type 2: a retrospective analysis of 55 patients","volume":"14","author":"Plotkin","year":"2011","journal-title":"J Neurosurg Spine"},{"key":"10.1007\/s13311-022-01277-w_bib84","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s11060-017-2690-7","article-title":"Spinal ependymomas in NF2: A surgical disease?","volume":"136","author":"Kalamarides","year":"2018","journal-title":"J Neurooncol"},{"key":"10.1007\/s13311-022-01277-w_bib85","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.jocn.2021.01.010","article-title":"Bevacizumab as a surgery-sparing agent for spinal ependymoma in patients with neurofibromatosis type II: Systematic review and case","volume":"86","author":"Snyder","year":"2021","journal-title":"J Clin Neurosci"},{"key":"10.1007\/s13311-022-01277-w_bib86","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/ane.12490","article-title":"Bevacizumab treatment for symptomatic spinal ependymomas in neurofibromatosis type 2","volume":"133","author":"Farschtschi","year":"2016","journal-title":"Acta Neurol Scand"},{"key":"10.1007\/s13311-022-01277-w_bib87","first-page":"215","article-title":"Revisiting neurofibromatosis type 2 diagnostic criteria to exclude LZTR1-related schwannomatosis.","volume":"88","author":"Smith","year":"2016","journal-title":"Neurology."},{"key":"10.1007\/s13311-022-01277-w_bib88","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s00401-020-02230-x","article-title":"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis","volume":"141","author":"Mansouri","year":"2021","journal-title":"Acta Neuropathol"},{"key":"10.1007\/s13311-022-01277-w_bib89","first-page":"1","article-title":"What to know about schwannomatosis: a literature review","volume":"2","author":"Schraepen","year":"2020","journal-title":"Br J Neurosurg"},{"key":"10.1007\/s13311-022-01277-w_bib90","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1200\/EDBK_208341","article-title":"Recent advances in lynch syndrome: diagnosis, treatment, and cancer prevention","volume":"38","author":"Yurgelun","year":"2018","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1007\/s13311-022-01277-w_bib91","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/GRF.0b013e3182185a41","article-title":"Lynch syndrome","volume":"54","author":"Backes","year":"2011","journal-title":"Clin Obstet Gynecol"},{"key":"10.1007\/s13311-022-01277-w_bib92","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1007\/s10147-018-1282-7","article-title":"Current clinical topics of Lynch syndrome","volume":"24","author":"Tanakaya","year":"2009","journal-title":"Int J Clin Oncol"},{"key":"10.1007\/s13311-022-01277-w_bib93","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1136\/jmedgenet-2014-102284","article-title":"Diagnostic criteria for constitutional mismatch repair deficiency syndrome: suggestions of the European consortium \u2018care for CMMRD' (C4CMMRD)","volume":"51","author":"Wimmer","year":"2014","journal-title":"J Med Genet"},{"key":"10.1007\/s13311-022-01277-w_bib94","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1158\/1078-0432.CCR-17-0574","article-title":"Clinical management and tumor surveillance recommendations of inherited mismatch repair deficiency in childhood","volume":"23","author":"Tabori","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1007\/s13311-022-01277-w_bib95","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nrm1907","article-title":"The multifaceted mismatch-repair system","volume":"7","author":"Jiricny","year":"2006","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1007\/s13311-022-01277-w_bib96","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1136\/jmedgenet-2015-103299","article-title":"Constitutional mismatch repair deficiency syndrome: clinical description in a French cohort","volume":"52","author":"Lavoine","year":"2015","journal-title":"J Med Genet"},{"key":"10.1007\/s13311-022-01277-w_bib97","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.ejca.2013.12.005","article-title":"Genetic and clinical determinants of constitutional mismatch repair deficiency syndrome: report from the constitutional mismatch repair deficiency consortium","volume":"50","author":"Bakry","year":"2014","journal-title":"Eur J Cancer"},{"key":"10.1007\/s13311-022-01277-w_bib98","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1053\/j.gastro.2017.02.011","article-title":"Recommendations on Surveillance and Management of Biallelic Mismatch Repair Deficiency (BMMRD) Syndrome: a Consensus Statement by the US Multi-Society Task Force on Colorectal Cancer","volume":"152","author":"Durno","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1007\/s13311-022-01277-w_bib99","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1093\/jnci\/djj073","article-title":"PMS2 mutations in childhood cancer","volume":"98","author":"De","year":"2006","journal-title":"J Natl Cancer Inst"},{"key":"10.1007\/s13311-022-01277-w_bib100","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1136\/jmg.2007.048942","article-title":"Familial T-cell non-Hodgkin lymphoma caused by biallelic MSH2 mutations.","author":"Scott","year":"2007","journal-title":"J Med Genet."},{"key":"10.1007\/s13311-022-01277-w_bib101","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1097\/MPH.0b013e318161aa20","article-title":"Biallelic PMS2 mutations and a distinctive childhood cancer syndrome","volume":"30","author":"Me","year":"2008","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1007\/s13311-022-01277-w_bib102","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/sj.ejhg.5201923","article-title":"Homozygous PMS2 germline mutations in two families with early-onset haematological malignancy, brain tumours, HNPCC-associated tumours, and signs of neurofibromatosis type 1","volume":"16","author":"Kruger","year":"2008","journal-title":"Eur J Hum Genet"},{"key":"10.1007\/s13311-022-01277-w_bib103","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1002\/humu.20569","article-title":"Novel biallelic mutations in MSH6 and PMS2 genes: gene conversion as a likely cause of PMS2 gene inactivation","volume":"28","author":"Auclair","year":"2007","journal-title":"Hum Mutat"},{"key":"10.1007\/s13311-022-01277-w_bib104","first-page":"294","article-title":"Neurofibromatosis and early onset of cancers in hMLH1-deficient children","volume":"59","author":"Wang","year":"1999","journal-title":"Cancer Res"},{"key":"10.1007\/s13311-022-01277-w_bib105","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/pbc.25818","article-title":"Constitutional mismatch repair deficiency in Israel: high proportion of founder mutations in MMR genes and consanguinity","volume":"63","author":"Baris","year":"2016","journal-title":"Pediatr Blood Cancer"},{"key":"10.1007\/s13311-022-01277-w_bib106","first-page":"290","article-title":"Human MLH1 deficiency predisposes to hematological malignancy and neurofibromatosis type 1","volume":"59","author":"Ricciardone","year":"1999","journal-title":"Cancer Res"},{"key":"10.1007\/s13311-022-01277-w_bib107","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1159\/000320891","article-title":"Tuberous sclerosis complex renal disease","volume":"118","author":"Dixon","year":"2011","journal-title":"Nephron Exp Nephrol"},{"key":"10.1007\/s13311-022-01277-w_bib108","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1126\/science.277.5327.805","article-title":"Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34.","volume":"277","author":"Slegtenhorst","year":"1997","journal-title":"Science."},{"key":"10.1007\/s13311-022-01277-w_bib109","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/0092-8674(93)90618-Z","article-title":"European chromosome 16 tuberous sclerosis consortium, identification and characterization of the tuberous sclerosis gene on chromosome 16","volume":"75","year":"1993","journal-title":"Cell"},{"key":"10.1007\/s13311-022-01277-w_bib110","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/ncb999","article-title":"Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins.","volume":"5","author":"Zhang","year":"2003","journal-title":"Nat Cell Biol."},{"key":"10.1007\/s13311-022-01277-w_bib111","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/ana.25956","article-title":"Prevention of epilepsy in infants with tuberous sclerosis complex in the EPISTOP trial","volume":"89","author":"Kotulska","year":"2020","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-022-01277-w_bib112","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S0140-6736(08)61279-9","article-title":"Tuberous sclerosis","volume":"372","author":"Curatolo","year":"2008","journal-title":"Lancet"},{"key":"10.1007\/s13311-022-01277-w_bib113","first-page":"139","article-title":"Brain lesions in tuberous sclerosis complex","volume":"48","author":"Matyja","year":"2010","journal-title":"Review Folia Neuropathologica"},{"issue":"49","key":"10.1007\/s13311-022-01277-w_bib114","first-page":"243","article-title":"Iinternational Tuberous Sclerosis Complex Consensus Conference","volume":"2013","author":"Northrup H, Krueger DA; International Tuberous Sclerosis Complex Consensus Group. Tuberous sclerosis complex diagnostic criteria update: recommendations of the","year":"2012","journal-title":"Pediatr Neurol"},{"key":"10.1007\/s13311-022-01277-w_bib115","first-page":"128","article-title":"Neonatal subependymal giant cell astrocytoma: new case and review of literature","volume":"36","author":"Raju","year":"2007","journal-title":"PediatrNeurol"},{"key":"10.1007\/s13311-022-01277-w_bib116","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1007\/s00381-008-0681-x","article-title":"Congenital subependymal giant cell astrocytoma: clinical considerations and expression of radial glial cell markers in giant cells","volume":"24","author":"Phi","year":"2008","journal-title":"Childs Nerv Syst"},{"key":"10.1007\/s13311-022-01277-w_bib117","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1007\/s00381-002-0700-2","article-title":"Subependymal giant cell astrocytoma in children with tuberous sclerosis","volume":"19","author":"Cuccia","year":"2003","journal-title":"Childs Nerv Syst"},{"key":"10.1007\/s13311-022-01277-w_bib118","doi-asserted-by":"crossref","first-page":"651","DOI":"10.7863\/jum.2000.19.9.651","article-title":"Central nervous system tumor with associated uni-lateral ventriculomegaly: unusual prenatal presentation of subsequently diagnosed tuberous sclerosis","volume":"19","author":"Mitra","year":"2000","journal-title":"J Ultrasound Med"},{"key":"10.1007\/s13311-022-01277-w_bib119","doi-asserted-by":"crossref","first-page":"808","DOI":"10.3171\/2010.9.JNS10816","article-title":"Gamma knife surgery for subependymal giant cell astrocytomas: clinical article","volume":"114","author":"Park","year":"2011","journal-title":"J Neurosurg"},{"key":"10.1007\/s13311-022-01277-w_bib120","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.pediatrneurol.2009.09.008","article-title":"Basal ganglia location of subependymal giant cell astrocytomas in two infants","volume":"42","author":"Isik","year":"2010","journal-title":"Pediatr Neurol"},{"key":"10.1007\/s13311-022-01277-w_bib121","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1136\/adc.2005.081703","article-title":"Congenital subependymal giant cell astrocytoma diagnosed on fetal MRI","volume":"91","author":"Hussain","year":"2006","journal-title":"Arch Dis Child"},{"key":"10.1007\/s13311-022-01277-w_bib122","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.pediatrneurol.2015.01.004","article-title":"Use of mTOR inhibitor everolimus in three neonates for treatment of tumors associated with tuberous sclerosis complex","volume":"52","author":"Goyer","year":"2014","journal-title":"Pediatr Neurol"},{"key":"10.1007\/s13311-022-01277-w_bib123","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1007\/s00381-014-2555-8","article-title":"Congenital subependymal giant cell astrocytomas in patients with tuberous sclerosis complex","volume":"30","author":"Kotulska","year":"2014","journal-title":"Childs Nerv Syst"},{"key":"10.1007\/s13311-022-01277-w_bib124","doi-asserted-by":"crossref","first-page":"705","DOI":"10.3389\/fneur.2019.00705","article-title":"Clinical characteristics of subependymal giant cell astrocytoma in tuberous sclerosis complex","volume":"10","author":"Jansen","year":"2019","journal-title":"Front Neurol"},{"key":"10.1007\/s13311-022-01277-w_bib125","first-page":"439","article-title":"Subependymal giant cell astrocytoma: diagnosis, screening, and treatment","volume":"49","author":"Roth","year":"2013","journal-title":"Recommendations from the International Tuberous Sclerosis Complex Consensus Conference 2012. Pediatr Neurol"},{"key":"10.1007\/s13311-022-01277-w_bib126","first-page":"166","article-title":"Tuberous","volume":"46","author":"Randle","year":"2017","journal-title":"Sclerosis Complex: A Review Pediatric Annals"},{"key":"10.1007\/s13311-022-01277-w_bib127","first-page":"211","article-title":"Everolimus in the treatment of subependymal giant cell astrocytomas, angiomyolipomas, and pulmonary and skin lesions associated with tuberous sclerosis complex","volume":"7","author":"Ffranz","year":"2013","journal-title":"Biologics"},{"key":"10.1007\/s13311-022-01277-w_bib128","doi-asserted-by":"crossref","first-page":"0158476","DOI":"10.1371\/journal.pone.0158476","article-title":"Long-term use of everolimus in patients with tuberous sclerosis complex: final results from the EXIST-1 study","volume":"11","author":"Franz","year":"2016","journal-title":"PLoS ONE"},{"key":"10.1007\/s13311-022-01277-w_bib129","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1016\/S0140-6736(16)31419-2","article-title":"Adjunctive everolimus therapy for treatment resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study.","volume":"388","author":"French","year":"2016","journal-title":"Lancet."},{"key":"10.1007\/s13311-022-01277-w_bib130","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1038\/s41390-020-1002-7","article-title":"Congenital subependymal giant cell astrocytoma in children with tuberous sclerosis complex: growth patterns and neurological outcome","volume":"89","author":"Chan","year":"2009","journal-title":"Pediatr Res"},{"key":"10.1007\/s13311-022-01277-w_bib131","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13023-019-1012-x","article-title":"Efficacy and safety of mTOR inhibitors (rapamycin and its analogues) for tuberous sclerosis complex: a meta-analysis","volume":"14","author":"Zhou","year":"2019","journal-title":"Orphanet J Rare Dis"},{"key":"10.1007\/s13311-022-01277-w_bib132","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1185\/03007995.2012.658907","article-title":"Outcomes of resecting subependymal giant cell astrocytoma (SEGA) among patients with SEGA-related tuberous sclerosis complex: a national claims database analysis","volume":"28","author":"Sun","year":"2012","journal-title":"Curr Med Res Opin"},{"key":"10.1007\/s13311-022-01277-w_bib133","first-page":"15","article-title":"The effect of everolimus on subependymal giant cell astrocytoma (SEGA) in children with tuberous sclerosis complex","volume":"15","author":"Bakhtiary","year":"2021","journal-title":"Iran J Child Neurol"},{"key":"10.1007\/s13311-022-01277-w_bib134","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/nrc3844","article-title":"VHL, the story of a tumour suppressor gene","volume":"15","author":"Gossage","year":"2015","journal-title":"Nat Rev Cancer"},{"key":"10.1007\/s13311-022-01277-w_bib135","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0039-6257(01)00245-4","article-title":"von Hippel-Lindau disease","volume":"46","author":"Singh","year":"2001","journal-title":"Surv Ophthalmol"},{"key":"10.1007\/s13311-022-01277-w_bib136","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/ejhg.2010.175","article-title":"Lindau disease: a clinical and scientific review","volume":"19","author":"Maher","year":"2011","journal-title":"Eur J Hum Genet"},{"key":"10.1007\/s13311-022-01277-w_bib137","doi-asserted-by":"crossref","first-page":"20","DOI":"10.15586\/jkcvhl.2017.88","article-title":"A review of Von Hippel-Lindau Syndrome","volume":"4","author":"Varshney","year":"2017","journal-title":"J Kidney Cancer"},{"key":"10.1007\/s13311-022-01277-w_bib138","doi-asserted-by":"crossref","first-page":"11661","DOI":"10.1073\/pnas.95.20.11661","article-title":"pVHL19 is a biologically active product of the von Hippel-Lindau gene arising from internal translation initiation","volume":"95","author":"Iliopoulos","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1007\/s13311-022-01277-w_bib139","first-page":"865","volume":"8","author":"Kaelin","year":"2008","journal-title":"The von Hippel-Lindau tumour suppressor protein: O2 sensing and cancer"},{"key":"10.1007\/s13311-022-01277-w_bib140","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/S0140-6736(04)15957-6","article-title":"Resche F. von Hippel-Lindau disease","volume":"363","author":"Richard","year":"2004","journal-title":"Lancet"},{"key":"10.1007\/s13311-022-01277-w_bib141","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/20459","article-title":"The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis","volume":"399","author":"Maxwell","year":"1999","journal-title":"Nature"},{"key":"10.1007\/s13311-022-01277-w_bib142","series-title":"Von Hippel-Lindau Syndrome","author":"Van Leeuwaarde","year":"1993"},{"key":"10.1007\/s13311-022-01277-w_bib143","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/B978-0-444-62702-5.00010-X","article-title":"Von Hippel-Lindau disease","volume":"132","author":"Chittiboina","year":"2015","journal-title":"Handb Clin Neurol"},{"key":"10.1007\/s13311-022-01277-w_bib144","doi-asserted-by":"crossref","first-page":"263","DOI":"10.5858\/arpa.2013-0520-RS","article-title":"Endocrine manifestations of von Hippel-Lindau disease","volume":"139","author":"Cassol","year":"2015","journal-title":"Arch Pathol Lab Med"},{"key":"10.1007\/s13311-022-01277-w_bib145","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.rcl.2015.12.004","article-title":"von Hippel-Lindau disease: review of genetics and imaging.","volume":"54","author":"Shanbhogue","year":"2016","journal-title":"Radiol Clin North Am."},{"key":"10.1007\/s13311-022-01277-w_bib146","doi-asserted-by":"crossref","first-page":"480","DOI":"10.3171\/jns.2004.100.3.0480","article-title":"Endolymphatic sac tumors in von Hippel-Lindau disease","volume":"100","author":"Choo","year":"2004","journal-title":"J Neurosurg"},{"key":"10.1007\/s13311-022-01277-w_bib147","first-page":"258","article-title":"Aldin E Saad, Capizzano A A, Policeni B, Sato Y, Moritani T","volume":"37","author":"Vijapura","year":"2016","journal-title":"Genetic syndromes associated with central nervous system tumors"},{"issue":"1","key":"10.1007\/s13311-022-01277-w_bib148","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1086\/302726","article-title":"Mosaicism in von Hippel-Lindau disease: lessons from kindreds with germline mutations identified in offspring with mosaic parents","volume":"66","author":"Sgambati","year":"2000","journal-title":"Am J Hum Genet"},{"key":"10.1007\/s13311-022-01277-w_bib149","doi-asserted-by":"crossref","first-page":"586857","DOI":"10.3389\/fendo.2020.586857","article-title":"The VHL\/HIF axis in the development and treatment of pheochromocytoma\/paraganglioma.","volume":"11","author":"Peng","year":"2020","journal-title":"Front Endocrinol (Lausanne)."},{"key":"10.1007\/s13311-022-01277-w_bib150","unstructured":"vhl alliance active surveillance guidelines for vhl syndrome. 2020.\u00a0https:\/\/www.vhlgr.org\/content\/91\/vhla-suggested-active-surveillance-guide_lines-d-\/."},{"key":"10.1007\/s13311-022-01277-w_bib151","article-title":"Von Hippel-Lindau syndrome.","author":"Frantzen","year":"2015","journal-title":"GeneReviews."},{"key":"10.1007\/s13311-022-01277-w_bib152","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1586\/ern.11.124","article-title":"Management of von Hippel-Lindau disease-associated CNS lesions","volume":"11","author":"Wind","year":"2011","journal-title":"Expert Rev Neurother"},{"key":"10.1007\/s13311-022-01277-w_bib153","unstructured":"In: FDA approves belzutifan for cancers associated with von Hippel-Lindau disease [online]. Available at: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-belzutifan-cancers-associated-von-hippel-lindau-disease. Accessed 13 Aug 2021."},{"key":"10.1007\/s13311-022-01277-w_bib154","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJM198705213162101","article-title":"Breast and other cancers in families with ataxia-telangiectasia","volume":"316","author":"Swift","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1007\/s13311-022-01277-w_bib155","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s11060-006-9275-1","article-title":"Genetic variation in p53 and ATM haplotypes and risk of glioma and meningioma","volume":"82","author":"Malmer","year":"2007","journal-title":"J Neurooncol"},{"key":"10.1007\/s13311-022-01277-w_bib156","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/258427a0","article-title":"Ataxia telangiectasia: a human mutation with abnormal radiation sensitivity","volume":"258","author":"Taylor","year":"1975","journal-title":"Nature"},{"key":"10.1007\/s13311-022-01277-w_bib157","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1158\/1078-0432.CCR-17-0465","article-title":"Recommendations for childhood cancer screening and surveillance in DNA repair disorders","volume":"23","author":"Walsh","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1007\/s13311-022-01277-w_bib158","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1002\/mds.25126","article-title":"A randomized trial of oral betamethasone to reduce ataxia symptoms in ataxia telangiectasia","volume":"27","author":"Zannolli","year":"2012","journal-title":"Mov Disord"},{"key":"10.1007\/s13311-022-01277-w_bib159","first-page":"79","article-title":"Proton spectroscopy and imaging at 3T in ataxia telangiectasia","volume":"28","author":"Wallis","year":"2007","journal-title":"AJNR Am J Neuroradiol"},{"key":"10.1007\/s13311-022-01277-w_bib160","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/B978-0-444-62702-5.00014-7","article-title":"Ataxia telangiectasia","volume":"132","author":"Nissenkorn","year":"2015","journal-title":"Handb Clin Neurol"},{"key":"10.1007\/s13311-022-01277-w_bib161","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/0140-6736(92)90868-4","article-title":"Location of gene for Gorlin syndrome","volume":"339","author":"Farndon","year":"1992","journal-title":"Lancet"},{"key":"10.1007\/s13311-022-01277-w_bib162","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/S0092-8674(00)81268-4","article-title":"Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome","volume":"85","author":"Hahn","year":"1996","journal-title":"Cell"},{"key":"10.1007\/s13311-022-01277-w_bib163","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1126\/science.272.5268.1668","article-title":"Human homolog of patched, a candidate gene for the basal cell nevus syndrome","volume":"272","author":"Johnson","year":"1996","journal-title":"Science"},{"key":"10.1007\/s13311-022-01277-w_bib164","doi-asserted-by":"crossref","first-page":"4155","DOI":"10.1200\/JCO.2014.58.2569","article-title":"Germline mutations in SUFU cause Gorlin syndrome-associated childhood medulloblastoma and redefine the risk associated with PTCH1 mutations","volume":"32","author":"Smith","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1007\/s13311-022-01277-w_bib165","first-page":"472","article-title":"Correlation of loss of heterozygosity at chromosome 9q with histological subtype in medulloblastomas","volume":"146","author":"Schofield","year":"1995","journal-title":"Am J Pathol"},{"key":"10.1007\/s13311-022-01277-w_bib166","first-page":"618","article-title":"Nevoid basal cell carcinoma syndrome: Relation with desmoplastic medulloblastoma in infancy","volume":"98","author":"Amlashi","year":"2003","journal-title":"A population-based study and review of the literature. Cancer"},{"key":"10.1007\/s13311-022-01277-w_bib167","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1038\/bjc.1991.435","article-title":"The incidence of Gorlin syndrome in 173 consecutive cases of medulloblastoma","volume":"64","author":"Evans","year":"1991","journal-title":"Br J Cancer"},{"key":"10.1007\/s13311-022-01277-w_bib168","doi-asserted-by":"crossref","DOI":"10.1155\/2011\/217378","article-title":"Basal cell carcinomas in gorlin syndrome: a review of 202 patients","volume":"2011","author":"Jones","year":"2011","journal-title":"J Skin Cancer"},{"key":"10.1007\/s13311-022-01277-w_bib169","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1002\/1097-0142(197710)40:4+<1861::AID-CNCR2820400815>3.0.CO;2-9","article-title":"Genetic and environmental interactions","volume":"40","author":"Strong","year":"1977","journal-title":"Cancer"},{"key":"10.1007\/s13311-022-01277-w_bib170","doi-asserted-by":"crossref","first-page":"643","DOI":"10.3109\/02688699109002890","article-title":"Brain tumours and the occurrence of severe invasive basal cell carcinoma in first degree relatives with Gorlin syndrome","volume":"5","author":"Evans","year":"1991","journal-title":"Br J Neurosurg"},{"key":"10.1007\/s13311-022-01277-w_bib171","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1158\/1078-0432.CCR-17-0595","article-title":"Cancer surveillance in Gorlin Syndrome and rhabdoid tumor predisposition syndrome","volume":"23","author":"Foulkes","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1007\/s13311-022-01277-w_bib172","doi-asserted-by":"crossref","first-page":"49","DOI":"10.2350\/14-07-1531-MISC.1","article-title":"Rhabdoid tumor predisposition syndrome.","volume":"18","author":"Sredni","year":"2015","journal-title":"Pediatr Dev Pathol."},{"key":"10.1007\/s13311-022-01277-w_bib173","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/1078-0432.CCR-10-1795","article-title":"Frequent hSNF5\/INIl germline mutations in patients with rhabdoid tumor","volume":"17","author":"Bourdeaut","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1007\/s13311-022-01277-w_bib174","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/pbc.22831","article-title":"Spectmm of SMARCB 1\/INI 1 mutations in familial and sporadic rhabdoid tumors","volume":"56","author":"Eaton","year":"2011","journal-title":"Pediatr Blood Cancer"},{"key":"10.1007\/s13311-022-01277-w_bib175","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.ccell.2016.02.009","article-title":"Genome-wide profiles of extra-cranial malignant rhabdoid tumors reveal heterogeneity and dysregulated developmental pathways.","volume":"29","author":"Chun","year":"2016","journal-title":"Cancer Cell."},{"key":"10.1007\/s13311-022-01277-w_bib176","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.ccell.2016.02.001","article-title":"Atypical teratoid\/rhabdoid tumors are comprised of three epigenetic sub-groups with distinct enhancer landscapes","volume":"29","author":"Johann","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1007\/s13311-022-01277-w_bib177","doi-asserted-by":"crossref","first-page":"90","DOI":"10.5858\/arpa.2019-0633-OA","article-title":"SMARCA4\/BRG1-deficient non-small cell lung carcinomas: a case series and review of the literature","volume":"145","author":"Nambirajan","year":"2021","journal-title":"Arch Pathol Lab Med"},{"key":"10.1007\/s13311-022-01277-w_bib178","series-title":"GeneReviews\u00ae\u00a0[Internet]","first-page":"1993","article-title":"Rhabdoid tumor predisposition syndrome 2017 Dec 7.","author":"Nemes","year":"2017"},{"key":"10.1007\/s13311-022-01277-w_bib179","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1038\/sj.onc.1210302","article-title":"TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes","volume":"26","author":"Petitjean","year":"2007","journal-title":"Oncogene"},{"key":"10.1007\/s13311-022-01277-w_bib180","article-title":"Li-Fraumeni Syndrome.","author":"Schneider","year":"1993","journal-title":"GeneReviews\u00ae[Internet]."},{"key":"10.1007\/s13311-022-01277-w_bib181","doi-asserted-by":"crossref","first-page":"27328919","DOI":"10.1002\/humu.23035","article-title":"TP53 variations in human cancers: new lessons from the IARC TP53 database and genomics data","volume":"37","author":"Bouaoun","year":"2016","journal-title":"Hum Mutat"},{"key":"10.1007\/s13311-022-01277-w_bib182","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1126\/science.1978757","article-title":"Germline p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms","volume":"250","author":"Malkin","year":"1990","journal-title":"Science"},{"key":"10.1007\/s13311-022-01277-w_bib183","first-page":"1","article-title":"Tumors associated with p53 germline mutations: a synopsis of 91 families","volume":"150","author":"Kleihues","year":"1997","journal-title":"Am J Pathol"},{"key":"10.1007\/s13311-022-01277-w_bib184","doi-asserted-by":"crossref","first-page":"8287","DOI":"10.1158\/0008-5472.CAN-05-4247","article-title":"Joint effects of germ-line p53 mutation and sex on cancer risk in Li-Fraumeni syndrome","volume":"66","author":"Wu","year":"2006","journal-title":"Cancer Res"},{"key":"10.1007\/s13311-022-01277-w_bib185","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1086\/374567","article-title":"Germline p53 mutations in a cohort with childhood sarcoma: sex differences in cancer risk","volume":"72","author":"Hwang","year":"2003","journal-title":"Am J Hum Genet"},{"key":"10.1007\/s13311-022-01277-w_bib186","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s10549-020-05612-7","article-title":"Frequency of radiation-induced malignancies post-adjuvant radiotherapy for breast cancer in patients with Li-Fraumeni syndrome","volume":"181","author":"Le","year":"2020","journal-title":"Breast Cancer Res Treat"},{"key":"10.1007\/s13311-022-01277-w_bib187","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1158\/1078-0432.CCR-17-0408","article-title":"Cancer screening recommendations for individuals with Li-Fraumeni Syndrome","volume":"23","author":"Kratz","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1007\/s13311-022-01277-w_bib188","doi-asserted-by":"crossref","first-page":"5658","DOI":"10.1210\/jcem.86.12.8070","article-title":"Guidelines for diagnosis and therapy of MEN type 1 and type 2","volume":"86","author":"Brandi","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1007\/s13311-022-01277-w_bib189","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1126\/science.276.5311.404","article-title":"Positional cloning of the gene for multiple endocrine neoplasia type 1","volume":"276","author":"Chandrasekharappa","year":"1997","journal-title":"Science"},{"key":"10.1007\/s13311-022-01277-w_bib190","doi-asserted-by":"crossref","first-page":"2990","DOI":"10.1210\/jc.2012-1230","article-title":"Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1)","volume":"97","author":"Thakker","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1007\/s13311-022-01277-w_bib191","first-page":"143","article-title":"Rubinstein-Taybi syndrome: clinical and molecular cytogenetic studies","volume":"46","author":"Hou","year":"2005","journal-title":"Acta Paediatr Taiwan"},{"key":"10.1007\/s13311-022-01277-w_bib192","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1038\/376348a0","article-title":"Rubinstein-Taybi syndrome caused by mutations in the transcriptional co-activator CBP","volume":"376","author":"Petrij","year":"1995","journal-title":"Nature"},{"key":"10.1007\/s13311-022-01277-w_bib193","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1007\/s00018-005-5555-8","article-title":"Rubinstein-Taybi syndrome: molecular findings and therapeutic approaches to improve cognitive dysfunction","volume":"63","author":"Hallam","year":"2006","journal-title":"Cell Mol Life Sci"},{"key":"10.1007\/s13311-022-01277-w_bib194","unstructured":"Stevens CA, Adam MP, Ardinger HH, et al. Rubinstein-Taybi Syndrome. Seattle (WA; University of Washington, Seattle. (PMID;1993.20301699\u201320301699)."},{"key":"10.1007\/s13311-022-01277-w_bib195","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/(SICI)1096-8628(20000515)92:2<136::AID-AJMG11>3.0.CO;2-S","article-title":"Investigation of germline PTEN, p53, p16(INK4A)\/p14(ARF), and CDK4 alterations in familial glioma.","volume":"92","author":"Tachibana","year":"2000","journal-title":"Am J Med Genet."},{"key":"10.1007\/s13311-022-01277-w_bib196","first-page":"149","article-title":"Hidden association of Cowden syndrome","volume":"3","author":"Yakubov","year":"2016","journal-title":"PTEN mutation and meningioma frequency Oncoscience"},{"key":"10.1007\/s13311-022-01277-w_bib197","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1093\/jnci\/djt277","article-title":"Cowden syndrome and the PTEN hamartoma tumor syndrome: systematic review and revised diagnostic criteria","volume":"105","author":"Pilarski","year":"2013","journal-title":"J Natl Cancer Inst"},{"key":"10.1007\/s13311-022-01277-w_bib198","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1212\/WNL.43.9.1728","article-title":"A familial syndrome with cutaneous malignant melanoma and cerebral astrocytoma","volume":"43","author":"Kaufman","year":"1993","journal-title":"Neurology"},{"key":"10.1007\/s13311-022-01277-w_bib199","doi-asserted-by":"crossref","first-page":"9818","DOI":"10.1158\/0008-5472.CAN-06-0494","article-title":"EA High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL.","volume":"66","author":"Goldstein","year":"2006","journal-title":"Cancer Res."},{"key":"10.1007\/s13311-022-01277-w_bib200","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1136\/jmedgenet-2015-103446","article-title":"An interstitial deletion within 9p21.3 and extending beyond CDKN2A predisposes to melanoma, neural system tumours and possible haematological malignancies.","volume":"53","author":"Baker","year":"2016","journal-title":"J Med Genet."},{"key":"10.1007\/s13311-022-01277-w_bib201","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1002\/gcc.1159","article-title":"CDKN2A germline splicing mutation affecting both p16(ink4) and p14(arf) RNA processing in a melanoma\/neurofibroma kindred.","volume":"31","author":"Petronzelli","year":"2001","journal-title":"Genes Chromosomes Cancer."},{"key":"10.1007\/s13311-022-01277-w_bib202","doi-asserted-by":"crossref","first-page":"3963","DOI":"10.1158\/0008-5472.CAN-06-2004","article-title":"Characterization of a germ-line deletion, including the entire INK4\/ARF locus, in a melanoma-neural system tumor family: identification of ANRIL, an antisense noncoding RNA whose expression coclusters with ARF","volume":"67","author":"Pasmant","year":"2007","journal-title":"Cancer Res"},{"key":"10.1007\/s13311-022-01277-w_bib203","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/1471-2350-15-59","article-title":"3 deletion in a girl affected by astrocytoma and multiple melanoma.","volume":"15","author":"Frigerio","year":"2014","journal-title":"BMC Med Genet."},{"key":"10.1007\/s13311-022-01277-w_bib204","doi-asserted-by":"crossref","first-page":"213","DOI":"10.5414\/NP301022","article-title":"Familial melanoma-astrocytoma syndrome: synchronous diffuse astrocytoma and pleomorphic xanthoastrocytoma in a patient with germline CDKN2A\/B deletion and a significant family history","volume":"36","author":"Chan","year":"2017","journal-title":"Clin Neuropathol"},{"key":"10.1007\/s13311-022-01277-w_bib205","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s00401-019-01997-y","article-title":"An update on the central nervous system manifestations of DICER1 syndrome","volume":"139","author":"de Kock","year":"2020","journal-title":"Acta Neuropathol"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-022-01277-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13311-022-01277-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923001319?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923001319?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-022-01277-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T06:36:27Z","timestamp":1761806187000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747923001319"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":205,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S1878747923001319"],"URL":"https:\/\/doi.org\/10.1007\/s13311-022-01277-w","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nervous system (NS) Tumors in Cancer Predisposition Syndromes","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s13311-022-01277-w","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2022 The American Society for Experimental NeuroTherapeutics, Inc. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}